The available data sets from the two existing comparability studies were assessed to conclude on the comparability of CMC2-CMC4.Differences in material quality were assessed and discussed with respect to changes in CQAs and a potential impact on safety, efficacy, PK, immunogenicity, and stability.A more detailed analysis of the potential changes in product quality, with special emphasis on the individual CQAs and potentially resulting changes in biological properties was performed with an extended set of analytical methods that have been shown to be capable of detecting micro-heterogeneities of the product during previous comparability exercises and product characterization.